Istodax romidepsin: Phase II data

An open-label, international, pivotal Phase II trial in 130 patients showed that Istodax produced an ORR of 26%, including 17 complete responses and 17 partial responses. The median duration of response for all responders was 12 months. The most common >=grade 3 adverse events were thrombocytopenia, neutropenia, infections and anemia. Patients received 14 mg/m 2 Istodax as a 4-hour infusion on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles. Data were presented at the American Society of Hematology meeting in Orlando. ...